Literature DB >> 7201387

High sensitivity to calcitonin of prolactin-secreting control in lactating rats.

V R Olgiati, C Netti, F Guidobono, A Pecile.   

Abstract

The effects of intracerebroventricular (icv;25ng/rat) or iv (10 micrograms/kg) salmon calcitonin (sCT) on PRL secretion were determined in lactating rats and compared to the effects in intact or ovariectomized-estrogen-treated female rats. The icv or iv injections of sCT 9 days after estrogen treatment did not significantly lower the PRL levels in intact rats. In ovariectomized-estrogen-primed animals, sCT (icv or iv) did not modify the afternoon surge of PRL secretion when injected during the surge, nor did it delay or attenuate the increasing secretory activity when administered (iv) before the afternoon surge had begun. On the contrary, 30 or 60 min after the icv or iv administration of sCT to lactating rats, suckling-induced PRL secretion was prevented. These results and our previous evidence that a greater dose of sCT is needed to decrease the less intense morphine- or stress-induced PRL secretion indicate differential hypoprolactinemic properties of sCT, which are particularly striking during lactation. While the mechanisms underlying these selective activities deserve further investigation, the proposed participation of PRL in the regulation of calcium metabolism during lactation suggests that the potent PRL inhibitory effect of CT in this condition should be regarded as one factor in the complex mechanism that prevents bone loss and protects the maternal skeleton.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7201387     DOI: 10.1210/endo-111-2-641

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  1 in total

1.  Increased forearm bone mineral content after bromocriptine treatment in hyperprolactinemia.

Authors:  M P Caraceni; E Corghi; S Ortolani; S Casazza; A D'Alberton; T Motta
Journal:  Calcif Tissue Int       Date:  1985-12       Impact factor: 4.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.